UNSPSC 51162704: Bromhexine

This classification denotes an expectorant with the molecular formula C14H20Br2N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Q1J152VB1P, chemically known as 3,5-dibromo-nalpha-cyclohexyl-nalpha-methyltoluene-alpha-2-diamine but more generally known as bromhexine, which bears US NIH Compound Identifier 2442. Bromhexine most often comes in base, chloride, and hydrochloride forms. European Medicines Agency schedules Bromhexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05914MIG.

UNSPSC 51162704 Bromhexine is a Commodity code that encompasses pharmaceutical products and related medical supplies procured by state and local health and corrections agencies. Based on recent solicitation activity, state and local governments are buying parenteral pharmaceutical products—including intravenous solutions, total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN) formulations, naloxone, and drug deactivation systems—through competitive bidding processes. The Washington State Department of Corrections and Seminole County, Florida represent the issuing bodies active under this code; correctional and community health departments drive demand for both routine pharmaceutical inventory and emergency medical supplies.

Activity under the code is concentrated in the Pacific Northwest and Southeast. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026 (response due October 7, 2026 at 4:00 PM PST) for parenteral products, services, and equipment to supply eight correctional facilities across Washington state, with DOC anticipating multiple contract awards and up to three bidders per region over an initial term running November 26, 2026 through June 30, 2030. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the response deadline was July 26, 2023. The Washington procurement emphasizes state set-aside participation goals (5% small business, 10% minority-owned, 6% women-owned, 5% veteran-owned) and requires demonstrated experience with parenteral preparation, patient lab monitoring, and accelerated delivery timelines (PN bags within 24 hours, other parenteral products within 8 hours).